Breast Cancer: Assessing Response to Neoadjuvant Chemotherapy by Using US-guided Near-Infrared Tomography
Abstract
Our initial findings indicate that pretreatment breast tumor hemoglobin content is a strong predictor of response to neoadjuvant chemotherapy and that the percentage of total hemoglobin changes normalized to the pretreatment level can be used to further differentiate responders from nonresponders in early treatment cycles.
Purpose
To assess initial breast tumor hemoglobin (Hb) content before the initiation of neoadjuvant chemotherapy, monitor the Hb changes at the end of each treatment cycle, and correlate these findings with tumor pathologic response.
Materials and Methods
The HIPAA-compliant study protocol was approved by the institutional review boards of both institutions. Written informed consent was obtained from all patients. Patients who were eligible for neoadjuvant chemotherapy were recruited between December 2007 and May 2011, and their tumor Hb content was assessed by using a near-infrared imager coupled with an ultrasonography (US) system. Thirty-two women (mean age, 48 years; range, 32–82 years) were imaged before treatment, at the end of every treatment cycle, and before definitive surgery. The patients were graded in terms of their final pathologic response on the basis of the Miller-Payne system as nonresponders and partial responders (grades 1–3) and near-complete and complete responders (grades 4 and 5). Tumor vascularity was assessed from total Hb (tHb), oxygenated Hb (oxyHb), and deoxygenated Hb (deoxyHb) concentrations. Tumor vascularity changes during treatment were assessed from percentage tHb normalized to the pretreatment level. A two-sample two-sided t test was used to calculate the P value and to evaluate statistical significance between groups. Bonferroni-Holm correction was applied to obtain the corrected P value for multiple comparisons.
Results
There were 20 Miller-Payne grade 1–3 tumors and 14 grade 4 or 5 tumors. Mean maximum pretreatment tHb, oxyHb, and deoxyHb levels were significantly higher in grade 4 and 5 tumors than in grade 1–3 tumors (P = .005, P = .008, and P = .017, respectively). The mean percentage tHb changes were significantly higher in grade 4 or 5 tumors than in grade 1–3 tumors at the end of treatment cycles 1–3 (P = .009 and corrected P = .009, P = .002 and corrected P = .004, and P < .001 and corrected P < .001, respectively).
Discussion
These findings indicate that initial tumor Hb content is a strong predictor of final pathologic response. Additionally, the tHb changes during early treatment cycles can further predict final pathologic response.
© RSNA, 2012
Supplemental material: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.12112415/-/DC1
References
- 1 . Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15(7):2483–2493.
- 2 . Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;(30):96–102.
- 3 . Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26(5):778–785.
- 4 . Preoperative assessment of prognostic factors in breast cancer. J Clin Pathol 2001;54(1):20–24.
- 5 . Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 2007;25(30):4772–4778.
- 6 . Predicting response to neoadjuvant chemotherapy in breast cancer: molecular imaging, systemic biomarkers and the cancer metabolome (review). Oncol Rep 2008;20(4):699–703.
- 7 . Endocrine therapy: current benefits and limitations. Breast Cancer Res Treat 2005;93(Suppl 1):S3–S10.
- 8 . Trastuzumab and breast cancer: developments and current status. Int J Clin Oncol 2006;11(3):199–208.
- 9 . Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg 2006;243(2):257–264.
- 10 . Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol 2011;29(6):660–666.
- 11 . The influence of preoperative MRI on breast cancer treatment. Ann Surg Oncol 2012;19(2):536–540.
- 12 . Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim. Eur J Nucl Med Mol Imaging 2011;38(3):419–425.
- 13 . Imaging in breast cancer: diffuse optics in breast cancer—detecting tumors in pre-menopausal women and monitoring neoadjuvant chemotherapy. Breast Cancer Res 2005;7(6):279–285.
- 14 . Breast cancer detection based on incremental biochemical and physiological properties of breast cancers: a six-year, two-site study. Acad Radiol 2005;12(8):925–933.
- 15 . Characterization of female breast lesions from multi-wavelength time-resolved optical mammography. Phys Med Biol 2005;50(11):2489–2502.
- 16 . Time-domain scanning optical mammography. I. Recording and assessment of mammograms of 154 patients. Phys Med Biol 2005;50(11):2429–2449.
- 17 . Electromagnetic breast imaging: results of a pilot study in women with abnormal mammograms. Radiology 2007;243(2):350–359.
- 18 . Benign versus malignant breast masses: optical differentiation with US-guided optical imaging reconstruction. Radiology 2005;237(1):57–66.
- 19 . Phase-contrast diffuse optical tomography: pilot results in the breast. Acad Radiol 2008;15(7):859–866.
- 20 . Differentiation of benign and malignant breast tumors by in-vivo three-dimensional parallel-plate diffuse optical tomography. J Biomed Opt 2009;14(2):024020.
- 21 . Early-stage invasive breast cancers: potential role of optical tomography with US localization in assisting diagnosis. Radiology 2010;256(2):367–378.
- 22 . Combined optical and X-ray tomosynthesis breast imaging. Radiology 2011;258(1):89–97.
- 23 . Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy. Proc Natl Acad Sci U S A 2007;104(10):4014–4019.
- 24 . Diffuse optical monitoring of blood flow and oxygenation in human breast cancer during early stages of neoadjuvant chemotherapy. J Biomed Opt 2007;12(5):051903.
- 25 . Noninvasive monitoring of breast cancer during neoadjuvant chemotherapy using optical tomography with ultrasound localization. Neoplasia 2008;10(10):1028–1040.
- 26 . Evaluation of breast tumor response to neoadjuvant chemotherapy with tomographic diffuse optical spectroscopy: case studies of tumor region-of-interest changes. Radiology 2009;252(2):551–560.
- 27 . Functional imaging using diffuse optical spectroscopy of neoadjuvant chemotherapy response in women with locally advanced breast cancer. Clin Cancer Res 2010;16(9):2605–2614.
- 28 . Optical imaging of breast cancer oxyhemoglobin flare correlates with neoadjuvant chemotherapy response one day after starting treatment. Proc Natl Acad Sci U S A 2011;108(35):14626–14631.
- 29 . Ultrasound-guided optical tomographic imaging of malignant and benign breast lesions: initial clinical results of 19 cases. Neoplasia 2003;5(5):379–388.
- 30 . Imaging tumor angiogenesis by use of combined near-infrared diffusive light and ultrasound. Opt Lett 2003;28(5):337–339.
- 31 . A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 2003;12(5):320–327.
- 32 . Optimal probing of optical contrast of breast lesions of different size located at different depths by US localization. Technol Cancer Res Treat 2006;5(4):365–380.
- 33 . Imaging heterogeneous absorption distribution of advanced breast cancer by optical tomography. J Biomed Opt 2010;15(6):066007.
- 34 . Imaging tumor oxyhemoglobin and deoxyhemoglobin concentrations with ultrasound-guided diffuse optical tomography. Technol Cancer Res Treat 2011;10(5):417–429.
- 35 . Vascularity change and tumor response to neoadjuvant chemotherapy for advanced breast cancer. Ultrasound Med Biol 2008;34(6):857–866.
Article History
Received November 18, 2011; revision requested January 16, 2012; revision received April 24; accepted May 7; final version accepted August 23.Published online: Feb 2013
Published in print: Feb 2013